Comparative Pharmacology
Head-to-head clinical analysis: FARXIGA versus GLYXAMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FARXIGA versus GLYXAMBI.
FARXIGA vs GLYXAMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose.
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
10 mg orally once daily, with or without food.
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
None Documented
None Documented
Terminal elimination half-life 12-13 hours; supports once-daily dosing. Steady-state reached in 5 days.
Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels.
Renal (33% as parent, 66% as glucuronide conjugates in urine); fecal (1.5% as parent); biliary (minor).
Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor/DPP-4 Inhibitor Combination Antidiabetic